Abstract | BACKGROUND AND OBJECTIVES: DESIGN AND METHODS: RESULTS: A significant decrease in pulmonary pressure and improvement in exercise capacity and functional class were observed in all patients. No significant adverse events were reported. INTERPRETATION AND CONCLUSIONS: These data, in a small group of patients, indicate that sildenafil citrate is effective in the treatment of PH in hemoglobinopathies that cannot be treated with alternative oral drugs and is well tolerated long-term at a daily dose of 100 mg, though studies including more patients may uncover toxicities and limitations of efficacy.
|
Authors | Giorgio Derchi, Gian Luca Forni, Francesco Formisano, Maria Domenica Cappellini, Renzo Galanello, Giandomenico D'Ascola, Patrizio Bina, Carmelo Magnano, Martina Lamagna |
Journal | Haematologica
(Haematologica)
Vol. 90
Issue 4
Pg. 452-8
(Apr 2005)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 15820939
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Piperazines
- Purines
- Sulfones
- Vasodilator Agents
- Sildenafil Citrate
|
Topics |
- Administration, Oral
- Adult
- Blood Transfusion
- Clinical Trials as Topic
- Dose-Response Relationship, Drug
- Echocardiography, Doppler
- Female
- Hemoglobinopathies
(complications)
- Humans
- Hypertension, Pulmonary
(complications, drug therapy)
- Male
- Piperazines
(adverse effects, therapeutic use)
- Priapism
(chemically induced, drug therapy)
- Purines
- Severity of Illness Index
- Sildenafil Citrate
- Sulfones
- Vasodilator Agents
(adverse effects, therapeutic use)
|